Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Overview of attention for article published in New England Journal of Medicine, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news: 51 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 132 X users
patent: 1 patent

facebook: 2 Facebook pages
reddit: 4 Redditors
guideline: 8 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 626 Mendeley

So far, Altmetric has seen 148 X posts from 132 X users, with an upper bound of 623,557 followers.

RT @drteplinsky: @SoMeCME KEYNOTE-826 Safety Key takeaway: KEYNOTE-826 safety consistent w/ known profiles Common grade ≥3 TRAEs: Cytopen…

@SoMeCME KEYNOTE-826 Safety Key takeaway: KEYNOTE-826 safety consistent w/ known profiles Common grade ≥3 TRAEs: Cytopenias Hypertension Watch for irAEs: Hypo- & hyperthyroidism Colitis Skin reactions First interim analysis: https://t.co/0LSGhcO…

@obgyntommy 頸がんの試験が T + C or P + pembro ±bevでしたが、この話ではなくです？？ https://t.co/mc3qbBYFY4

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 144 additional X posts.